Patricia Van Arnum

Editorial Director, DCAT

[email protected]
Patricia Van Arnum is Editorial Director at the Drug, Chemical & Associated Technologies Association (DCAT), where she is responsible for delivering informational services for DCAT members. She is editor of DCAT Value Chain Insights, DCAT’s editorial newsletter providing news and analysis of the business of bio/pharmaceutical development and manufacturing covering the full spectrum of the bio/pharmaceutical manufacturing value chain. She also provides content advisement and support for DCAT’s volunteer committees. Overall, she has 30 years of experience covering the Bio/Pharmaceutical, Fine-Chemical and Chemical industries as a business and science editor. She is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science and holds undergraduate degrees in chemistry, economics, and political science.

LATEST

AI & Digital Transformation: Where Does the Bio/Pharma Industry Stand?
By

By
How AI and other digital tools are progressing across the bio/pharmaceutical industry is top of mind. Key perspectives on the use and potential of AI and other digital tools were shared at the DCAT Global Summit.

Injectables: Market & Technology Trends
By

By
What are key trends for injectable drugs and the related market impact? From switches from IV-administered to subcutaneous drug delivery and increased interest for home and self administration, DCAT Value Chain Insights provides the latest. 

What’s on the Minds of CEOs & Their Priorities?
By

By
A recent KPMG study of CEOs of large companies, including 400 US companies, found that supply-chain cost reduction and AI integration and upskilling are top priorities of CEOs. How are companies addressing these challenges? 

Biomanufacturing Growth: Capacity Trends & CDMO Insights & Outlook
By

By
What is the outlook for biomanufacturing (drug substance)? How is industry capacity trending, and what is the outlook for outsourcing? A recent study by BioPlan Associates reveals key insights.

PhRMA Raises A Legal Challenge To Most-Favored-Nation Drug Pricing
By

By
The Pharmaceutical Research and Manufacturers of America (PhRMA) has filed a legal complaint that challenges the US government’s most-favored-nation drug pricing policy in the GLOBE Model under Medicare Part B.

What Is New and Upcoming in Small-Molecule Drugs?
By

By
Which small-molecule drugs are making the mark in 2026 in new drug approvals or in recently or soon-to-be launched drugs? DCAT Value Chain Insights takes an inside look.

US Gov’t Makes Next Move to Onshore Mfg of Generics
By

By
The White House is moving to identify new and unused domestic, US-based, and near-shore production capacity to meet a goal of localizing manufacturing of essential medicines.

How Autonomous Will the Supply Chain Be?
By

By
A recent analysis by Gartner projects low uptake of AI for autonomous supply-chain planning decisions by 2030, but AI does factor into the workflows of the top 25 supply-chain organizations, according to the firm’s annual rankings, but how?

Novo at a Crossroads: Will Its Strategic Plan Deliver?
By

By
Novo’s CEO Mike Doustdar laid out a strategic growth plan for the company, which included a plan to launch more than five multi-blockbusters by 2030 and expand beyond its obesity and diabetes franchise. Will he and the company be able to deliver?

Innovation & Pharma: The Molecules & Companies
By

By
How truly innovative is the bio/pharma industry? What products, modalities, and companies are behind that innovation? Looking at “first-in-class” new drug approvals, defined as drugs with new mechanisms of action over existing drugs, reveals an interesting picture.